Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer's disease

Alzheimer's and Dementia

Volumn 10, Issue 5, 2014, Pages S425-S429.e1

  Perneczky, Robert ^a,b,c   Alexopoulos, Panagiotis ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b WEST LONDON MENTAL HEALTH NHS TRUST   (United Kingdom)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Amyloid precursor protein; Amyloid ; Biomarker; Correlation; Dementia; Diagnosis; Mild cognitive impairment; Prognosis; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; BIOLOGICAL MARKER; PHOSPHOPROTEIN; PHOSPHORYLATED TAU 181; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); APP PROTEIN, HUMAN; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT; SECRETASE;

AGED; ALZHEIMER DISEASE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATIONAL STUDY; DEMENTIA; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MULTICENTER STUDY (TOPIC); NERVE FIBER DEGENERATION; NEUROIMAGING; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN FUNCTION; PROTEIN METABOLISM; BLOOD; CEREBROSPINAL FLUID; CLINICAL TRIAL (TOPIC); FACTUAL DATABASE; METABOLISM; NERVE DEGENERATION; NERVE FIBER; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ACID ENDOPEPTIDASES; AXONS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; PEPTIDE FRAGMENTS; PHOSPHORYLATION; TAU PROTEINS;

EID: 84908247852     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.09.006     Document Type: Article

References (23)

1. J. Hardy, and D.J. Selkoe The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297 2002 353 356
2. R. Vassar BACE1: the beta-secretase enzyme in Alzheimer's disease J Mol Neurosci 23 2004 105 114
3. H. Zetterberg, U. Andreasson, O. Hansson, G. Wu, S. Sankaranarayanan, and M.E. Andersson Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease Arch Neurol 65 2008 1102 1107
4. Z. Zhong, M. Ewers, S. Teipel, K. Burger, A. Wallin, and K. Blennow Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment Arch Gen Psych 64 2007 718 726
5. U.S. Food and Drug Administration draft guidance for industry, clinical investigators, and Food and Drug Administration staff - design considerations for pivotal clinical investigations for medical devices 2011 U.S. Food and Drug Administration Rockwell, MD
6. J.H. Kang, M. Korecka, J.B. Toledo, J.Q. Trojanowski, and L.M. Shaw Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-beta(1-42) and tau proteins as Alzheimer disease biomarkers Clin Chem 59 2013 903 916
7. G. Wu, S. Sankaranarayanan, S.H. Hsieh, A.J. Simon, and M.J. Savage Decrease in brain soluble amyloid precursor protein beta (sAPPbeta) in Alzheimer's disease cortex J Neurosci Res 89 2011 822 832
8. G. Wu, S. Sankaranarayanan, K. Tugusheva, J. Kahana, G. Seabrook, and X.P. Shi Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer's subjects Clin Biochem 41 2008 986 996
9. C. Rosen, U. Andreasson, N. Mattsson, J. Marcusson, L. Minthon, and N. Andreasen Cerebrospinal fluid profiles of amyloid beta-related biomarkers in Alzheimer's disease Neuromolecular Med 14 2012 65 73
10. G. Wu, S. Sankaranarayanan, J. Wong, K. Tugusheva, M.S. Michener, and X. Shi Characterization of plasma beta-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease J Neurosci Res 90 2012 2247 2258
11. P. Lewczuk, J. Popp, N. Lelental, H. Kolsch, W. Maier, and J. Kornhuber Cerebrospinal fluid soluble amyloid-beta protein precursor as a potential novel biomarkers of Alzheimer's disease J Alzheimers Dis 28 2012 119 125
12. R. Perneczky, A. Tsolakidou, A. Arnold, J. Diehl-Schmid, T. Grimmer, and H. Forstl CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease Neurology 77 2011 35 38
13. G. Brinkmalm, A. Brinkmalm, P. Bourgeois, R. Persson, O. Hansson, and E. Portelius Soluble amyloid precursor protein alpha and beta in CSF in Alzheimer's disease Brain Res 1513 2013 117 126
14. A. Olsson, K. Hoglund, M. Sjogren, N. Andreasen, L. Minthon, and L. Lannfelt Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients Exp Neurol 183 2003 74 80
15. M. Ewers, Z. Zhong, K. Burger, A. Wallin, K. Blennow, and S.J. Teipel Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease Brain 131 2008 1252 1258
16. A. Tsolakidou, P. Alexopoulos, L.H. Guo, T. Grimmer, C. Westerteicher, and M. Kratzer -Site amyloid precursor protein-cleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tau Alzheimers Dement 9 2013 386 391
17. S.D. Mulder, W.M. van der Flier, J.H. Verheijen, C. Mulder, P. Scheltens, and M.A. Blankenstein BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology J Alzheimers Dis 20 1 2010 253 260
18. T. Grimmer, M. Faust, F. Auer, P. Alexopoulos, H. Forstl, and G. Henriksen White matter hyperintensities predict amyloid increase in Alzheimer's disease Neurobiol Aging 33 2012 2766 2773
19. M.J. Figurski, T. Waligorska, J. Toledo, H. Vanderstichele, M. Korecka, and V.M. Lee Improved protocol for measurement of plasma beta-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients Alzheimers Dement 8 2012 250 260
20. R. Perneczky, L.H. Guo, S.M. Kagerbauer, L. Werle, A. Kurz, and J. Martin Soluble amyloid precursor protein beta as blood-based biomarker of Alzheimer's disease Transl Psychiatry 3 2013 e227
21. A. Mullard Sting of Alzheimer's failures offset by upcoming prevention trials Nat Rev Drug Discov 11 2012 657 660
22. S. Kim, S. Swaminathan, L. Shen, S.L. Risacher, K. Nho, and T. Foroud Genome-wide association study of CSF biomarkers A{beta}1-42, t-tau, and p-tau181p in the ADNI cohort Neurology 76 2011 69 79
23. L.M. Shaw, H. Vanderstichele, M. Knapik-Czajka, C.M. Clark, P.S. Aisen, and R.C. Petersen Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects Ann Neurol 65 2009 403 413